Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Probing the CB1 cannabinoid receptor binding pocket with AM6538, a high-affinity irreversible antagonist.

Laprairie RB, Vemuri K, Stahl EL, Korde A, Ho JH, Grim TW, Hua T, Wu Y, Stevens RC, Liu ZJ, Makriyannis A, Bohn LM.

Mol Pharmacol. 2019 Sep 12. pii: mol.119.116483. doi: 10.1124/mol.119.116483. [Epub ahead of print]

2.

Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.

Neuropharmacology. 2019 Jun;151:1-12. doi: 10.1016/j.neuropharm.2019.03.033. Epub 2019 Mar 30.

PMID:
30940536
3.

Inflammation and CB2 signaling drive novel changes in the ocular lipidome and regulate immune cell activity in the eye.

Toguri JT, Leishman E, Szczesniak AM, Laprairie RB, Oehler O, Straiker AJ, Kelly MEM, Bradshaw HB.

Prostaglandins Other Lipid Mediat. 2018 Nov;139:54-62. doi: 10.1016/j.prostaglandins.2018.09.004. Epub 2018 Sep 16.

PMID:
30232034
4.

The effect of quinine in two bottle choice procedures in C57BL6 mice: Opioid preference, somatic withdrawal, and pharmacokinetic outcomes.

Grim TW, Park SJ, Schmid CL, Laprairie RB, Cameron M, Bohn LM.

Drug Alcohol Depend. 2018 Oct 1;191:195-202. doi: 10.1016/j.drugalcdep.2018.05.034. Epub 2018 Aug 2.

PMID:
30138791
5.

Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.

Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB.

Br J Pharmacol. 2019 May;176(10):1455-1469. doi: 10.1111/bph.14440. Epub 2018 Aug 10.

PMID:
29981240
6.

Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.

Bagher AM, Laprairie RB, Kelly MEM, Denovan-Wright EM.

Methods Mol Biol. 2018;1780:549-571. doi: 10.1007/978-1-4939-7825-0_25.

PMID:
29856035
7.

Huntington's disease pattern of transcriptional dysregulation in the absence of mutant huntingtin is produced by knockout of neuronal GLT-1.

Laprairie RB, Petr GT, Sun Y, Fischer KD, Denovan-Wright EM, Rosenberg PA.

Neurochem Int. 2019 Feb;123:85-94. doi: 10.1016/j.neuint.2018.04.015. Epub 2018 Apr 27.

PMID:
29709465
8.

The future of type 1 cannabinoid receptor allosteric ligands.

Alaverdashvili M, Laprairie RB.

Drug Metab Rev. 2018 Feb;50(1):14-25. doi: 10.1080/03602532.2018.1428341. Epub 2018 Jan 21.

PMID:
29355038
9.

Differential regulation of the duplicated fabp7, fabp10 and fabp11 genes of zebrafish by peroxisome proliferator activated receptors.

Laprairie RB, Denovan-Wright EM, Wright JM.

Comp Biochem Physiol B Biochem Mol Biol. 2017 Nov;213:81-90. doi: 10.1016/j.cbpb.2017.08.003. Epub 2017 Aug 24.

PMID:
28844908
10.

Approaches to Assess Biased Signaling at the CB1R Receptor.

Laprairie RB, Stahl EL, Bohn LM.

Methods Enzymol. 2017;593:259-279. doi: 10.1016/bs.mie.2017.06.031. Epub 2017 Jul 5.

PMID:
28750807
11.

Bidirectional allosteric interactions between cannabinoid receptor 1 (CB1) and dopamine receptor 2 long (D2L) heterotetramers.

Bagher AM, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM.

Eur J Pharmacol. 2017 Oct 15;813:66-83. doi: 10.1016/j.ejphar.2017.07.034. Epub 2017 Jul 19.

PMID:
28734930
12.

Crystal structures of agonist-bound human cannabinoid receptor CB1.

Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho JH, Han GW, Ding K, Li X, Liu H, Hanson MA, Zhao S, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Nature. 2017 Jul 27;547(7664):468-471. doi: 10.1038/nature23272. Epub 2017 Jul 5.

13.

Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.

Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM, Thakur GA.

ACS Chem Neurosci. 2017 Jun 21;8(6):1188-1203. doi: 10.1021/acschemneuro.6b00310. Epub 2017 Feb 7.

PMID:
28103441
14.

Cannabinoid receptor ligand bias: implications in the central nervous system.

Laprairie RB, Bagher AM, Denovan-Wright EM.

Curr Opin Pharmacol. 2017 Feb;32:32-43. doi: 10.1016/j.coph.2016.10.005. Epub 2016 Nov 9. Review.

PMID:
27835801
15.

Crystal Structure of the Human Cannabinoid Receptor CB1.

Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A, Laprairie RB, Stahl EL, Ho JH, Zvonok N, Zhou H, Kufareva I, Wu B, Zhao Q, Hanson MA, Bohn LM, Makriyannis A, Stevens RC, Liu ZJ.

Cell. 2016 Oct 20;167(3):750-762.e14. doi: 10.1016/j.cell.2016.10.004.

16.

Subfunctionalization of peroxisome proliferator response elements accounts for retention of duplicated fabp1 genes in zebrafish.

Laprairie RB, Denovan-Wright EM, Wright JM.

BMC Evol Biol. 2016 Jul 16;16(1):147. doi: 10.1186/s12862-016-0717-x.

17.
18.

Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.

Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM.

Mol Pharmacol. 2016 Jun;89(6):652-66. doi: 10.1124/mol.116.103465. Epub 2016 Apr 6.

PMID:
27053685
19.

Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.

Laprairie RB, Kulkarni AR, Kulkarni PM, Hurst DP, Lynch D, Reggio PH, Janero DR, Pertwee RG, Stevenson LA, Kelly ME, Denovan-Wright EM, Thakur GA.

ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25.

20.

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM.

Mol Pharmacol. 2016 Mar;89(3):364-75. doi: 10.1124/mol.115.101980. Epub 2015 Dec 23. Erratum in: Mol Pharmacol. 2016 Jun;89(6):694.

PMID:
26700564

Supplemental Content

Loading ...
Support Center